Aug 13, 2020
Global Market and Forecast Model for Hepatitis C Tests Market 2020 with Coverage of 39 Countries
Mar 19, 2020
FDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C
Mar 10, 2020
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
Mar 06, 2020
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Feb 26, 2020
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
Jan 31, 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Jan 10, 2020
Technological Advancements Expand Biopharmaceuticals' Production Capabilities
Oct 08, 2019
Clinicians Not Consistent With Guidelines When Managing HIV/HCV Coinfection
Sep 26, 2019
FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
Sep 26, 2019
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
Jul 08, 2019
Intent Solutions Joins University of Kentucky Program to Eliminate Hepatitis C in Appalachia
May 30, 2019
Taiwan National Health Insurance Adminstration of the Ministry of Health and Welfare Approves Epclusa(R) (sofosbuvir/velpatasvir) for Reimbursement
Apr 30, 2019
FDA approves first treatment for all genotypes of hepatitis C in pediatric patients
Apr 15, 2019
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
Jan 02, 2019
Ascletis' IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA
Jan 01, 2019
Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu
Nov 12, 2018
The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir
Nov 09, 2018
AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset
Nov 05, 2018
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD
Oct 18, 2018
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA